{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:57:03Z","timestamp":1761490623655},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/ http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:p>Pediatric Burkitt lymphoma has historically been treated with intensive methotrexate-based chemotherapy, which improves patient survival while causing severe toxicities. Young patients typically have better outcomes with intensive therapies, while adults and immunocompromised patients have higher toxicities and worse outcomes. Newer treatment regimens, including etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab (EPOCH-R), show promise for these patients. However, few studies exist to demonstrate efficacy and improved toxicity profile with EPOCH-R. We present 2 cases: a 25-year-old male with Down syndrome and an 18-year-old male with Burkitt lymphoma and significant renal injury who were successfully treated with EPOCH-R with minimal toxicities.<\/jats:p>","DOI":"10.1097\/mph.0000000000001287","type":"journal-article","created":{"date-parts":[[2018,8,8]],"date-time":"2018-08-08T20:02:44Z","timestamp":1533758564000},"page":"498-500","source":"Crossref","is-referenced-by-count":4,"title":["Successful Use of EPOCH-R in 2 Young Adult Patients With Burkitt Lymphoma and Acute Kidney Injury: A Case Report"],"prefix":"10.1097","volume":"41","author":[{"given":"Savannah","family":"Ross","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristen","family":"Eisenman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly W.","family":"Maloney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230918","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1056\/NEJMoa1308392","article-title":"Low-intensity therapy in adults with Burkitt\u2019s lymphoma","volume":"369","author":"Dunleavy","year":"2013","journal-title":"N Engl J Med"},{"key":"R2-20230918","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/PAP.0b013e3182a92cde","article-title":"Burkitt lymphoma and MYC: what else is new?","volume":"21","author":"Said","year":"2014","journal-title":"Adv Anat Pathol"},{"key":"R3-20230918","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1182\/blood-2004-02-0405","article-title":"Adult Burkitt leukemia and lymphoma","volume":"104","author":"Blum","year":"2004","journal-title":"Blood"},{"key":"R4-20230918","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.pcl.2014.09.010","article-title":"Pediatric lymphomas and histiocytic disorders of childhood","volume":"62","author":"Allen","year":"2015","journal-title":"Pediatr Clin North Am"},{"key":"R5-20230918","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1002\/pbc.25137","article-title":"Assessment of renal function during high dose methotrexate treatment in children with acute lymphoblastic leukemia","volume":"61","author":"Ylinen","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"R6-20230918","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1200\/JCO.2000.18.3.547","article-title":"Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"18","author":"Kantarjian","year":"2000","journal-title":"J Clin Oncol"},{"key":"R7-20230918","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1093\/annonc\/mdt058","article-title":"Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group","volume":"24","author":"Wasterlid","year":"2013","journal-title":"Ann Oncol"},{"key":"R8-20230918","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1365-2141.2011.08846.x","article-title":"Acute lymphoblastic leukaemia in children with Down Syndrome: an updated review","volume":"155","author":"Maloney","year":"2011","journal-title":"Br J Haematol"},{"key":"R9-20230918","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.pcl.2014.09.009","article-title":"Down syndrome preleukemia and leukemia","volume":"62","author":"Maloney","year":"2015","journal-title":"Pediatr Clin North Am"},{"key":"R10-20230918","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/pbc.23371","article-title":"Myelosuppression and Infectious complications in children with Down Syndrome and acute lymphoblastic leukemia","volume":"58","author":"Rabin","year":"2012","journal-title":"Pediatr Blood Cancer"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00043426-201908000-00017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T04:32:45Z","timestamp":1695011565000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00043426-201908000-00017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000001287","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]}}}